Novo Nordisk CEO Says Brazil Business Is Struggling After Semaglutide Exclusivity Loss
The CEO said price is central in Brazil.
Related stories
Solstice Advanced Materials Q3 Earnings Snapshot
M impact | EQUITY | Nov 04, 2026, 11:11 AM UTC
Andersons to Acquire Harvestone for $915 Million
The Andersons agreed to acquire Harvestone Low Carbon Partners for $915 million. About half of the price is attributed to expected 45Z and 45Q tax credit cash flows; closing is exp
M impact | EQUITY | Nov 04, 2026, 11:08 AM UTC
ATS Corporation targets $65 million-$75 million in annualized cost savings
The company says its fixed-cost transformation program is expected to deliver $65 million-$75 million in annualized cost savings.
M impact | EQUITY | Nov 04, 2026, 11:07 AM UTC
New Pacific Metals' Quarterly Net Loss Widens 90% to USD 1.42 Million
New Pacific Metals reported a net loss of USD 1.42 million for the three months ended September 30, 2026, up 90% year-on-year.
M impact | EQUITY | Nov 04, 2026, 11:07 AM UTC
Vermilion Energy Reports Third-Quarter Loss per Share
M impact | EQUITY | Nov 04, 2026, 11:07 AM UTC
Nifty Smallcap 100 Rises 2%, Midcap 100 Gains 1.5%
Broader Indian equity benchmarks outperformed the Sensex and Nifty on Wednesday, November 4.
M impact | EQUITY | Nov 04, 2026, 11:06 AM UTC